175 related articles for article (PubMed ID: 38536615)
1. Quantification of Unencapsulated Drug in Target Tissues Demonstrates Pharmacological Properties and Therapeutic Effects of Liposomal Topotecan (FF-10850).
Kimura T; Okada K; Morohashi Y; Kato Y; Mori M; Kato H; Matsumoto T; Shimoyama S
Pharm Res; 2024 Apr; 41(4):795-806. PubMed ID: 38536615
[TBL] [Abstract][Full Text] [Related]
2. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
[TBL] [Abstract][Full Text] [Related]
3. Simple and efficient liposomal encapsulation of topotecan by ammonium sulfate gradient: stability, pharmacokinetic and therapeutic evaluation.
Liu JJ; Hong RL; Cheng WF; Hong K; Chang FH; Tseng YL
Anticancer Drugs; 2002 Aug; 13(7):709-17. PubMed ID: 12187327
[TBL] [Abstract][Full Text] [Related]
4. Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer.
Patankar NA; Waterhouse D; Strutt D; Anantha M; Bally MB
Invest New Drugs; 2013 Feb; 31(1):46-58. PubMed ID: 22615060
[TBL] [Abstract][Full Text] [Related]
5. Optimization of vincristine-topotecan combination--paving the way for improved chemotherapy regimens by nanoliposomes.
Zucker D; Barenholz Y
J Control Release; 2010 Sep; 146(3):326-33. PubMed ID: 20685223
[TBL] [Abstract][Full Text] [Related]
6. A Liposomal Gemcitabine, FF-10832, Improves Plasma Stability, Tumor Targeting, and Antitumor Efficacy of Gemcitabine in Pancreatic Cancer Xenograft Models.
Matsumoto T; Komori T; Yoshino Y; Ioroi T; Kitahashi T; Kitahara H; Ono K; Higuchi T; Sakabe M; Kori H; Kano M; Hori R; Kato Y; Hagiwara S
Pharm Res; 2021 Jun; 38(6):1093-1106. PubMed ID: 33961188
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo studies of different liposomes containing topotecan.
Hao YL; Deng YJ; Chen Y; Wang XM; Zhong HJ; Suo XB
Arch Pharm Res; 2005 May; 28(5):626-35. PubMed ID: 15974453
[TBL] [Abstract][Full Text] [Related]
8. Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts.
Serwer LP; Noble CO; Michaud K; Drummond DC; Kirpotin DB; Ozawa T; Prados MD; Park JW; James CD
Neuro Oncol; 2011 Dec; 13(12):1288-95. PubMed ID: 21954443
[TBL] [Abstract][Full Text] [Related]
9. FF-10850, a Novel Liposomal Topotecan Achieves Superior Antitumor Activity via Macrophage- and Ammonia-Mediated Payload Release in the Tumor Microenvironment.
Shimoyama S; Okada K; Kimura T; Morohashi Y; Nakayama S; Kemmochi S; Makita-Suzuki K; Matulonis UA; Mori M
Mol Cancer Ther; 2023 Dec; 22(12):1454-1464. PubMed ID: 37683276
[TBL] [Abstract][Full Text] [Related]
10. Insights into accelerated liposomal release of topotecan in plasma monitored by a non-invasive fluorescence spectroscopic method.
Fugit KD; Jyoti A; Upreti M; Anderson BD
J Control Release; 2015 Jan; 197():10-9. PubMed ID: 25456833
[TBL] [Abstract][Full Text] [Related]
11. The role of pH and ring-opening hydrolysis kinetics on liposomal release of topotecan.
Fugit KD; Anderson BD
J Control Release; 2014 Jan; 174():88-97. PubMed ID: 24231406
[TBL] [Abstract][Full Text] [Related]
12. Optimization of liposomal topotecan for use in treating neuroblastoma.
Chernov L; Deyell RJ; Anantha M; Dos Santos N; Gilabert-Oriol R; Bally MB
Cancer Med; 2017 Jun; 6(6):1240-1254. PubMed ID: 28544814
[TBL] [Abstract][Full Text] [Related]
13. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
Dadashzadeh S; Vali AM; Rezaie M
Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
[TBL] [Abstract][Full Text] [Related]
14. F7 and topotecan co-loaded thermosensitive liposome as a nano-drug delivery system for tumor hyperthermia.
Du C; Li S; Li Y; Galons H; Guo N; Teng Y; Zhang Y; Li M; Yu P
Drug Deliv; 2020 Dec; 27(1):836-847. PubMed ID: 32508162
[TBL] [Abstract][Full Text] [Related]
15. Ion-Pairing Contribution to the Liposomal Transport of Topotecan as Revealed by Mechanistic Modeling.
Fugit KD; Anderson BD
J Pharm Sci; 2017 Apr; 106(4):1149-1161. PubMed ID: 28007561
[TBL] [Abstract][Full Text] [Related]
16. Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience.
Grahn AY; Bankiewicz KS; Dugich-Djordjevic M; Bringas JR; Hadaczek P; Johnson GA; Eastman S; Luz M
J Neurooncol; 2009 Nov; 95(2):185-197. PubMed ID: 19466380
[TBL] [Abstract][Full Text] [Related]
17. In-vitro cytotoxicity, in-vivo biodistribution and anti-tumour effect of PEGylated liposomal topotecan.
Hao YL; Deng YJ; Chen Y; Wang KZ; Hao AJ; Zhang Y
J Pharm Pharmacol; 2005 Oct; 57(10):1279-87. PubMed ID: 16259756
[TBL] [Abstract][Full Text] [Related]
18. Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
Leonard SC; Lee H; Gaddy DF; Klinz SG; Paz N; Kalra AV; Drummond DC; Chan DC; Bunn PA; Fitzgerald JB; Hendriks BS
Anticancer Drugs; 2017 Nov; 28(10):1086-1096. PubMed ID: 28857767
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
Rowinsky EK; Grochow LB; Sartorius SE; Bowling MK; Kaufmann SH; Peereboom D; Donehower RC
J Clin Oncol; 1996 Apr; 14(4):1224-35. PubMed ID: 8648378
[TBL] [Abstract][Full Text] [Related]
20. In vitro assay for measuring real time topotecan release from liposomes: release kinetics and cellular internalization.
Gilabert-Oriol R; Chernov L; Anantha M; Dragowska WH; Bally MB
Drug Deliv Transl Res; 2017 Aug; 7(4):544-557. PubMed ID: 28432657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
